2m 2m 2m 2m 2m 2m 2m
ACUMEN PHARMA (ABOS)
NASDAQ
$2.31+$0.02 (+0.87%)
Price as of Jun 03, 2026 7:51 PM EDT- $187.8MMarket Cap
- 127.88%1-Year Change
- BiotechnologyIndustry
ACUMEN PHARMA (ABOS)
$2.31+$0.02 (+0.87%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | 10.8M N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 -100.00% | 10.8M N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -104.9M +11.82% | -93.8M +121.65% | -42.3M +30.77% | -32.4M +162.99% | |
Depreciation and Amortization Expense | 58,000 -7.94% | 63,000 +3.28% | 61,000 +90.63% | 32,000 +700.00% | |
Total Operating Expenses | 123.8M +8.61% | 114.0M +86.49% | 61.1M +35.15% | 45.2M +130.99% | |
Operating Profit | -123.8M +8.61% | -114.0M +86.49% | -61.1M +35.15% | -45.2M +130.99% | |
Interest Income | 7.4M -47.98% | 14.3M +32.68% | 10.8M N/A | N/A N/A | |
Interest Expense | -4.2M +4.00% | -4.1M +597.93% | -581,000 N/A | N/A N/A | |
Interest Income and Expense and Net | 3.2M -68.52% | 10.3M +0.51% | 10.2M N/A | 0 N/A | |
Total Nonoperating Income and Expense | 2.5M -78.64% | 11.7M +33.32% | 8.8M +268.21% | 2.4M +102.94% | |
Income before Taxes | -123.8M +8.61% | -114.0M +86.49% | -61.1M +35.15% | -45.2M +130.99% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -121.3M +18.57% | -102.3M +95.39% | -52.4M +22.20% | -42.9M -57.40% | |
Net Income from Continuing Operations Applicable to Common | -121.3M +18.57% | -102.3M +95.39% | -52.4M +22.20% | -42.9M -57.40% | |
Basic EPS and Net Income | -2.00 +16.96% | -1.71 +58.33% | -1.08 +1.89% | -1.06 -78.88% | |
Diluted EPS and Net Income | -2.00 +16.96% | -1.71 +58.33% | -1.08 +1.89% | -1.06 -78.88% | |
Basic Weighted Average Shares | 60.6M +0.91% | 60.0M +23.46% | 48.6M +19.72% | 40.6M +102.43% | |
Diluted Weighted Average Shares | 60.6M +0.91% | 60.0M +23.46% | 48.6M +19.72% | 40.6M +102.43% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 54.0M +51.54% | 35.6M -46.73% | 66.9M -48.59% | 130.1M +6.50% | |
Short-Term Investments | 62.9M -53.74% | 135.9M -23.05% | 176.6M +271.83% | 47.5M -34.09% | |
Cash and Cash Equivalents and Short-Term Investments | 116.9M -31.88% | 171.6M -29.55% | 243.5M +37.11% | 177.6M -8.56% | |
Total Current Assets | 122.3M -31.44% | 178.3M -27.70% | 246.6M +36.76% | 180.3M -9.23% | |
Accumulated Depreciation | 200,000 +100.00% | 100,000 N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 103,000 +41.10% | 73,000 -40.16% | 122,000 -26.06% | 165,000 +358.33% | |
Total Long-Term Assets | 350,000 -27.98% | 486,000 +119.91% | 221,000 +46.36% | 151,000 +978.57% | |
Total Assets | 122.8M -48.60% | 239.0M -22.94% | 310.1M +57.75% | 196.6M -14.65% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 8.8M N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 30.0M +8.69% | 27.6M +112.84% | 13.0M +66.04% | 7.8M +51.78% | |
Total Long-Term Debt | 22.4M -23.87% | 29.4M -1.60% | 29.9M N/A | N/A N/A | |
Total Long-Term Liabilities | 0 -100.00% | 150,000 -99.50% | 30.2M +28,643.81% | 105,000 N/A | |
Total Liabilities | 52.4M -8.35% | 57.2M +32.50% | 43.2M +452.38% | 7.8M +51.78% | |
Retained Earnings | -446.5M +37.32% | -325.1M +45.93% | -222.8M +30.73% | -170.4M +33.59% | |
Total Stockholders Equity | 70.4M -61.26% | 181.8M -31.90% | 267.0M +41.42% | 188.8M -16.17% | |
Total Shares Outstanding | 60.6M +0.80% | 60.1M +3.77% | 57.9M +41.16% | 41.0M +1.36% | |
Cash Flow | |||||
Cash from Operating Activities | -115.5M +34.01% | -86.2M +100.20% | -43.1M +22.50% | -35.2M +95.72% | |
Capital Expenditures | 88,000 +450.00% | 16,000 -23.81% | 21,000 -86.96% | 161,000 +302.50% | |
Cash from Investing Activities | 133.9M +178.87% | 48.0M +127.98% | -171.7M -538.10% | 39.2M +137.63% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -34,000 -100.49% | 6.9M -95.43% | 151.8M +3,784.13% | 3.9M -98.05% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | -566.56% N/A | N/A N/A | |
Return on Assets | -67.07% +79.95% | -37.27% +80.30% | -20.67% +2.96% | -20.08% N/A | |
Return on Equity | -96.20% +110.96% | -45.60% +98.42% | -22.98% +11.00% | -20.71% N/A | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 4.07 -36.92% | 6.46 -66.03% | 19.01 -17.64% | 23.08 N/A | |
Cash Ratio | 1.80 +39.42% | 1.29 -74.97% | 5.16 -69.04% | 16.65 N/A | |
Debt-to-Equity Ratio | 0.44 N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.25 N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow